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1014 Journal of Clinical Lipidology, Vol 11, No 4, August 2017concentrations. The presence of cardiovascular diseases and risk factors was defined by coded medical
records from primary care and hospital discharge databases.
RESULTS: The age- and sex-standardized prevalence of heterozygous FH-P and homozygous FH-P
were 1/192 individuals and 1/425,774 individuals, respectively. In the group aged 8 to 18 years, 0.46%
(95% confidence interval: 0.41–0.52) had FH-P; overall prevalence was 0.58% (95% confidence interval:
0.58–0.60). Among patients with FH-P aged .18 years, cardiovascular disease prevalence was 3.5 times
higher than in general population, and CHD prevalence in those aged 35 to 59 years was 4.5 times higher
than in those without FH-P. Lipid-lowering therapy was lacking in 13.5% of patients with FH-P, and only
31.6% of men and 22.7 of women were receiving high or very high-intensity lipid-lowering therapy.
CONCLUSION: Prevalence of FH-P was higher than expected, but underdiagnosed and suboptimally
treated, especially in women. Moreover, treatment started late considering the high CHD incidence asso-
ciated with this condition.
 2017 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Familial hypercholesterolemia (FH) is an autosomal
dominant disorder associated with premature coronary heart
disease (CHD).1 If untreated, men with FH have a 50% risk
of fatal or nonfatal CHD by 50 years of age, whereas un-
treated women are at 30% risk at 60 years.1 Prevalence of
heterozygous FH (HeFH) and homozygous FH (HoFH) in
general population has been estimated at 1:500 and
1:1,000,000 respectively,2 except in regions with high con-
sanguinity rates, such as South Africa, Lebanon, and
Quebec, where prevalence is close to 1/100. However, recent
population studies disagree with these classical prevalence
rates, reporting estimates of 1/200 to 1/250.3–6 Despite this
uncertainty, FH is a major public health concern, and studies
assessing its prevalence and clinical characteristics in Medi-
terranean populations7 are lacking.
Knowledge about population prevalence and identifica-
tion of clinical characteristics related to the FH phenotypes
(FH-Ps) associated with high risk of cardiovascular dis-
eases (CVD) is a priority for the development of health
policies to minimize the disease burden, both to relieve FH
effects on the population and to optimize the use of
therapeutic resources. The present study aimed to estimate
FH prevalence and to describe its clinical characteristics in
a European Mediterranean population.Methods
Study design
A cross-sectional study was carried out using data from
2,554,644 patients.
Data source
The Information System for the Development of
Research in Primary Care (Catalan acronym: SIDIAP) isa clinical database of anonymized longitudinal records
containing the information collected from 6,177,972 pa-
tients between 2005 and 2014. This database includes
information on the clinical activity of 3414 general
practitioners and 853 primary care pediatricians in the
274 primary care practices of the Catalan Institute of
Health, a public entity providing healthcare coverage to
85% of the population in Catalonia (Spain).8
The information recorded includes demographic and
lifestyle factors, along with diagnoses (International Clas-
sification of Diseases [ICD-10]), hospital discharge
information (ICD-9), laboratory tests, and prescribed
medications dispensed by community pharmacies. The
quality of SIDIAP data for research use has been previously
documented, and the database has been widely used to
study the epidemiology of CVD and risk factors.9–11 The
authors state that this study complies with the Declaration
of Helsinki, and ethics approval for observational research
using SIDIAP data was obtained from a local ethics
committee.
Inclusion criteria
All SIDIAP records for individuals aged $8 years, alive
on December 2014, and with at least 1 low-density
lipoprotein cholesterol (LDL-C) measurement between
2006 and 2014 were eligible for inclusion.
Exclusion criteria
Patients with a history of hypothyroidism, nephrotic
syndrome, or basal triglyceride values $400 mg/dL were
excluded.
Variables and definitions
Participants were defined as receiving lipid-lowering
therapy (LLT) if their records showed at least 2 purchases
of statin or ezetimibe within the 6 months before their
Zamora et al Familial hypercholesterolemia in Europe 1015LDL-C measurement. Adherence to treatment was calcu-
lated according to the Medical Possession Ratio: number of
days of statin supply during 6 consecutive months divided
by 183 days. The descriptive analysis classified patients’
statin or ezetimibe exposure according to the cholesterol
reduction capacity of the drug, as follows: low, ,30%;
moderate, 30% to 50%; high, 50% to 60%; and very high,
.60%.12
The untreated LDL-C measurement closest to December
2014 in each patient record was used to estimate FH-P
prevalence. LDL-C was considered untreated if there was
no record of LLT purchases during at least 6 months before
the LDL-C test. We used 10 multiple imputations by
chained equations to replace missing pretreated LDL-C13
in individuals with no record of untreated LDL-C (ie,
they consistently purchased medication). The imputation
of pretreated cholesterol levels for participants on medica-
tion at baseline has been shown to yield estimates consis-
tent with reports of randomized clinical trials.13 The
variables included in the imputation model were age, sex,
dose and type of LLT, treatment adherence (purchasing re-
cord), and the presence of diabetes mellitus. The LDL-C
measurement closest to December 2014 was used to
describe the level of LDL-C control, independently of
LLT treatment.
Definition of case
It was impossible to make a diagnosis based on the full
Dutch Lipid Clinic Network score because the SIDIAP
database does not include information on familial history of
premature CVD, presence of cholesterol deposits, or
genetic tests. Thus, we defined FH according to validated
age-adjusted LDL-C thresholds14 and refer to individuals
with FH as FH-P patients. In adults, HeFH-P was defined
as untreated LDL-C .230 mg/dL for 18- to 30-year-olds;
.239 mg/dL for 30- to 39-year-olds, .269 mg/dL for
40- to 48-year-olds, and .255 mg/dL for participants
aged .48 years.14 For all adults, HoFH-P was defined by
LDL-C values $500 mg/dL.2 In children and adolescents
(aged 8–18 years), FH was defined by LDL-C values
.190.7
CVD were defined as a composite of CHD (myocardial
infarction, cardiac revascularization, or angina), periph-
eral arterial disease, and stroke. Diagnoses were deter-
mined using ICD-10 and ICD-9 codes obtained from
primary care and hospital discharge records. The presence
of cardiovascular risk factors (CVRF) diabetes mellitus,
hypertension, hypercholesterolemia, and smoking were
also determined from ICD-10 and ICD-9 codes in primary
care and hospital discharge records. The following vari-
ables were also obtained from SIDIAP: baseline age, sex,
systolic and diastolic blood pressure (SBP and DBP,
respectively), body mass index, and laboratory tests: total
cholesterol, LDL-C, high-density lipoprotein cholesterol,
triglycerides, glucose, glycosylated hemoglobin (HBA1c),
and creatinine.Statistical analyses
Results were expressed as percentages for categorical
variables and compared using the chi-square test; continuous
variables are reported as mean and standard deviation (SD),
or median (quartiles) and compared using Student t-test or
Mann–Whitney test. Prevalence was standardized by age
and sex using the 2014 European population age and sex dis-
tribution.15 The association of CVRF and of CVD with FH-P
was assessed using logistic regression models. Statistical
analysis was carried out using R software.16Results
At least 1 LDL-C measurement was recorded for each of
the 2,764,917 individuals in the SIDIAP database. Of these,
2,554,644 patients fulfilled all inclusion criteria
(Supplementary Fig. 1).
The FH-P definition criteria identified 14,699 individ-
uals. The observed global FH-P prevalence was 0.58%
(95% confidence interval [CI]: 0.58–0.60), or 1/172 in-
dividuals. The age- and sex-standardized prevalence of FH-
P was slightly lower: 0.52% (95% CI: 0.51–0.53; 1/192).
Prevalence of FH-P by age group and sex are represented in
Figure 1. Six patients fulfilled HoFH-P criteria, represent-
ing a prevalence of 1/425,774 individuals. Mean (SD) age
of these patients was 53.3 years (20.0), 50% of them
were women, and mean (SD) LDL-C was 535 mg/dL
(29.4). Fifty percent of patients presented hypertension,
1 in 3 presented diabetes. Two participants were under
statin therapy, 1 was a current smoker, and none of them
presented history of CVD.
Prevalence of FH-P among children aged 8 to 18 years
was 0.46% (95% CI: 0.41–0.52; 249 cases in 53,737
individuals). In this age range, 895 individuals had
LDL-C .160 mg/dL, considered the clinical threshold to
suspect FH in children.
The characteristics of the population with FH-P are
compared with the general population in Table 1, showing
that patients with FH-P were older and had higher preva-
lence of CVRF. Mean values for pretreated and treated
LDL-C by age group in the population with FH-P are
shown in Figure 2. Mean values were higher at younger
ages.
Among the FH-P population, 2578 patients had a history
of CVD (2077 of them CHD). Considering the general
population aged .18 years, patients with FH-P had 3.5
times higher CHD prevalence than the general population,
which increased to 4.5 in the group aged 35 to 59 years
(mean age 50.3 years); in the subgroup aged 35 to 44 years,
the CHD prevalence was 8.2 times higher in women and 6.4
times higher in men, compared with the population without
FH-P. Prevalence of CHD by sex, age group, and presence
of FH-P is shown in Figure 3. Regardless of the specific
CVD analyzed, the prevalence stratified by the presence
of FH-P did not differ by sex (Table 2).
Figure 1 Prevalence of familial hypercholesterolemia phenotype (FH-P) by age and sex.
1016 Journal of Clinical Lipidology, Vol 11, No 4, August 2017Clinical characteristics according to presence of CVD
are shown in Table 3. In the multivariate analysis, age and
classical CVRF, but not sex, were independently associated
with the presence of CHD in the population with FH-P
(Table 4).Table 1 Comparison of baseline characteristics of population with
population
FH phenotype
N 14,699
Age, mean (SD) 61.5 (15.6)
Male sex, % 45.9
Hypertension, % 50.3
Diabetes mellitus, % 19.7
Current smoker, % 38.1
Obesity, % 25.7
BMI, mean (SD) 28.3 (4.8)
Personal history of CVD, % 17.5
Personal history of CHD, % 11.8
Personal history of stroke, % 4.9
Personal history of PAD, % 4.3
Receiving lipid therapy, % 86.5
SBP mm Hg, mean (SD) 130.2 (15.4)
DBP mm Hg, mean (SD) 75.9 (10.1)
TC mg/dL, mean (SD) 254.7 (65.4)
Untreated LDL-C, mg/dL mean (SD) 284.1 (37.2)
LDL-C, mg/dL mean (SD) (LLT) 171.9 (60.2)
HDL-C, mg/dL mean (SD) 55.3 (13.8)
TG, mg/dL mean (SD) 153.9 (91.0)
HBA1c, mean (SD) 6.24 (1.4)
Creatinine, mean (SD) 0.92 (0.4)
BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular d
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cho
systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglThe mean (SD) age at CHD onset was 64.9 (12.4)
years for the whole study population, and 60.5 (12.0)
years in participants with FH-P. At CHD onset, 31% of
individuals were aged ,55 years, and 63% were aged
.65 years.familial hypercholesterolemia (FH) phenotype and general
General population P value
2,539,944
54.1 (18.7) ,.001
47.4 .004
33.6 ,.001
13.1 ,.001
35.9 ,.001
21.1 ,.001
27.5 (5.3) ,.001
8.1 ,.001
4.8 ,.001
2.6 ,.001
2.1 ,.001
19.2 ,.001
127.1 (15.5) ,.001
75.1 (10.3) ,.001
196.9 (39.5) ,.001
129.4 (38.0) ,.001
118.7 (33.8) ,.001
55.0 (14.9) ,.02
121.1 (74.9) ,.001
6.0 (1.2) ,.001
0.9 (0.3) ,.001
iseases; DBP, diastolic blood pressure; HBA1c, glycosylated hemoglobin;
lesterol; LLT, lipid-lowering therapy; PAD, peripheral artery disease; SBP,
ycerides.
Figure 2 Mean LDL-C values by age in population with familial hypercholesterolemia phenotype (FH-P), with and without lipid-
lowering therapy. LDL-C, Low-density lipoprotein cholesterol.
Zamora et al Familial hypercholesterolemia in Europe 1017We found that 13.5% of patients with FH-P were not
receiving LLT, but the proportion was 48.9% in participants
aged .45 years. Among those treated, 73.1% were taking
drugs with less than 50% lipid-lowering capacity; 24.5%
were receiving high-intensity LLT (50%–60% lipid-
lowering capacity); and 2.2% had a combined therapy,
with LDL-C lowering potency .60% (Table 5). Mean
LDL-C in patients with FH-P was 171.9 mg/dL; mean pre-
treated LDL-C was 284.1 mg/dL. On average, the percent-
age of participants who received high and very high-
intensity LLT was 9% points lower in women than in
men, regardless of age group. The Medical Possession Ra-
tio exceeded 80% in more than half (51.2%) of the study
participants with FH-P who were prescribed LLT.Discussion
This study describes an age- and sex-standardized FH-P
prevalence of 1/192 and 1/425,774 individuals (both het-
erozygous and homozygous, respectively) for the first time
in a European Mediterranean population. It is also the first
community-based study to assess the prevalence of FH-P in
children aged 8 to 18 years. We found that prevalence of
CHD was much higher in patients with FH-P than in the
general population, despite of this, up to 14.1% of patients
with FH-P were not under LLT, a gap that reached 48.9% in
participants aged ,45 years. These results suggest that FH-
P is underdiagnosed and its therapeutic management is
suboptimal and starts late.
HeFH-P prevalence
The observed prevalence of HeFH-P in our study is
higher than that estimated in earlier studies,2 similar to thatreported in recent years in other populations,5,6 and very
close to that reported in Northern Europe.3 The age- and
sex-standardized prevalence figures were slightly lower
than the crude prevalence because study participants were
slightly older than the reference population.
The use of age-adjusted LDL-C levels to diagnose FH,
in the absence of genetic criteria, has been previously
validated in our population, with reported sensitivity values
of 91% and positive predictive values (PPT) of 71% for the
diagnosis of FH.14 It appears that current FH-P criteria,
based on age-adjusted LDL-C levels, may lead to some
overestimation of the actual prevalence, mainly because
of polygenic hypercholesterolemia or combined familial
hyperlipidemia.
Only 3765 patients with FH are included in the official
Catalan registry of FH, representing a very small proportion
of all patients with FH according to the observed preva-
lence in this study, and only 1050 of them had undergone
the corresponding genetic examination. This underdetec-
tion is comparable to that of other countries with active FH
registers.2
Also in line with other studies,5,6 we observed differ-
ences in HeFH-P prevalence across age groups. This result
suggests that age could modulate the phenotypic expression
of the disease,6 as we based the FH-P diagnosis on LDL-C
levels. Although no sex-related differences in FH-P preva-
lence were observed in children, in 25- to 54-year-olds, the
prevalence was lower in women, probably due to the lower
LDL-C levels in premenopausal women.17
HoFH-P prevalence
We found a higher prevalence of HoFH-P than that
classically estimated in hospital patients, registry samples,
or calculations using the Hardy–Weinberg equation,2 and
Figure 3 Comparison of coronary heart disease (CHD) prevalence in the population with familial hypercholesterolemia phenotype (FH-
P) vs general population, and odds ratio of CHD in the FH-F population with respect to general population, by age and sex.
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population.18 Given the variability in the genetic expres-
siveness of patients with homozygous FH, and the use ofTable 2 Proportion of cardiovascular diseases by sex in individuals
Cardiovascular diseases Sex FH phenotype
N Men 6747
Women 7952
Coronary heart disease Men 17.6%
Women 7.0%
Peripheral artery disease Men 6.6%
Women 2.5%
Stroke Men 5.9%
Women 4.1%
Cardiovascular disease Men 24.6%
Women 11.6%
FH, familial hypercholesterolemia.LDL-C values .500 mg/dL to define the homozygous
FH, null and defective homozygous patients19 have prob-
ably been included in our study.with FH phenotype and general population
General population Ratio P value
1,203,924
1,336,021
7.0% 2.50 .80
2.9% 2.39
3.3% 2.00 .14
1.2% 2.13
3.2% 1.80 .13
2.1% 1.90
11.2% 2.19 .48
5.4% 2.12
Table 3 Comparison of baseline characteristics of population with FH phenotype, with and without CVD
With CVD Without CVD P value
N 2578 12,121
Age mean (SD) 69.3 (11.4) 59.0 (15.9) ,.001
Male sex % 64.3 42.0 ,.001
Hypertension % 74.4 45.1 ,.001
Diabetes mellitus % 34.8 16.5 ,.001
Current smoker % 52.9 35.4 ,.001
Obesity % 32.4 24.3 ,.001
BMI mean (SD) 29.1 (4.6) 28.2 (4.9) ,.001
Receiving lipid therapy % 97.8 84.1 ,.001
SBP mm Hg mean (SD) 132.2 (16.1) 129.9 (15.2) ,.001
DBP mm Hg mean (SD) 74.1 (10.3) 76.3 (10.0) ,.001
TC mg/dL mean (SD) 216.2 (56.2) 262.9 (64.3) ,.001
LDL-C mg/dL mean (SD) 137.0 (49.1) 179.4 (59.8) ,.001
Untreated LDL-C mg/dL mean (SD) 288.0 (35.5) 283.3 (37.5) ,.001
HDL-C mg/dL mean (SD) 50.8 (12.8) 56.3 (13.8) ,.001
TG mg/dL mean (SD) 153.9 (91.2) 154.8 (89.6) .4
HBA1c mean (SD) 6.5 (1.4) 6.2 (1.3) ,.001
Creatinine mean (SD) 1.06 (0.5) 0.9 (0.3) ,.001
BMI, body mass index; DBP, diastolic blood pressure; HBA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, Triglycerides.
Zamora et al Familial hypercholesterolemia in Europe 1019Prevalence of FH-P in children
To our knowledge, this is the largest study to estimate
FH-P prevalence in a European population including
children aged 8 to 14 years. However, only 7% of the
Catalan population aged between 8 and 14 years had a lipid
test including LDL-C on record, and many of them may
have been performed within an FH cascade screening, so
we cannot discard some selection bias affecting the
prevalence estimation. The FH-P prevalence in this group
is slightly lower than that observed in a sample of
American children.20 In general, the only lipid variable
measured in children is TC, but we chose to use LDL-C
because of its higher potential to diagnose FH-P.21 Sex-
specific LDL-C cut-off values are designed to be the mostTable 4 OR for association of coronary heart disease in the
population with familial hypercholesterolemia phenotype
(multivariate analysis)
Diagnostic OR (CI) P value
Age (10 y) 1.10 (1.14–1.18) ,.001
LDL-C (20 mg) 2.02 (1.90–2.04) ,.001
Diabetes 2.00 (1.90–2.04) ,.001
Hypertension 1.55 (1.48–1.62) ,.001
Creatinine (1 mg) 1.22 (1.14–1.29) ,.001
Smoking 1.16 (1.10–1.22) ,.001
Obesity 1.06 (1.01–1.11) .01
HDL-C (10 mg) 1.05 (1.03–1.07) ,.001
Triglycerides (20 mg) 1.03 (1.02–1.03) ,.001
Sex (men) 0.97 (0.92–1.02) .34
CI, confidence interval; HDL-C, high-density lipoprotein choles-
terol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio.accurate diagnostic tool to screen the relatives of patients
with FH when a genetic diagnosis is absent.22 The recom-
mendation of a universal screening criterion based on lipid
testing in children has generated controversy.22 Our find-
ings support at least opportunistic screening for the pediat-
ric population, and several authors have proposed that the
ideal screening strategy would be the integration of direct
and reverse screening cascades.23
FH-P, CVRF, and CVD
Participants with FH-P were older than the general
population without FH-P and had a higher prevalence of
CVRF. These differences in age and CVRF status coincide
with a previous report in the Spanish population.24 Diabetes
mellitus, hypertension, renal function, smoking, and
obesity proved to be important risk factors for CVD in pa-
tients with FH-P.2 Hence, a global approach is needed to
tackle CVRF levels in this population. However, high-
intensity LLT should be the management cornerstone, as
we observed a strong association between LDL-C levels
and the presence of CHD in patients with FH-P.
The CVRF prevalence in our study is higher than that
observed in SAFEHEART, a Spanish cohort study in a
population with HeFH (defined by genetic criteria),24 and
moreover, Besseling et al.25 found a lower prevalence of
diabetes in FH individuals than in normolipidemic patients.
This discrepancy could be explained by the older age of the
FH population in our study. In individuals with FH-P, we
would emphasize the observed CVD prevalence of 24.6%
in men, (17.6% CHD). In women, the CVD prevalence
was 11.6% (7% CHD). There were no differences between
men and women with FH-P in CVD prevalence, compared
Table 5 Distribution and use for age and LDL-C value of LLT in patients with familial hypercholesterolemia phenotype
Age groups (y) N % Treated Mean LDL-C (mg/dL) Low ,30% Moderate, 30%–50% High, 50%–60% Very high, .60%
8–14 160 15.6 219 69.5% 19.7% 4.0% 6.8%
15–24 207 28.0 218 23.5% 52.3% 22.1% 2.1%
25–34 452 43.6 224 8.4% 60.9% 24.9% 5.0%
35–44 1221 58.7 214 8.8% 65.1% 21.8% 4.1%
45–54 2024 82.1 191 8.8% 62.6% 26.0% 2.4%
55–64 3775 91.1 171 9.6% 63.3% 24.4% 2.4%
65–74 3920 96.3 155 10.4% 61.9% 25.4% 1.9%
75–84 2296 97.1 150 11.8% 61.9% 24.6% 1.4%
.84 644 96.0 154 15.1% 63.8% 19.8% 1.0%
LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy.
1020 Journal of Clinical Lipidology, Vol 11, No 4, August 2017with the general population. These results diverge from a
recent systematic review, in which the odds ratios for
CHD when comparing patients with FH vs non-FH patients
were 10.3 (95% CI: 7.8–13.8) in the subgroup treated with
LLT and 13.2 (95% CI: 10.0–17.4) in the nontreated pa-
tients.26 The younger age of the population in our study
might explain this discrepancy. Within the population
aged 35 to 59 years (with a mean age of 50.3 years), the
prevalence of CHD was 4.75 times higher in patients
with FH-P, compared with general population. This differ-
ence was even more remarkable in women with FH-P. In
the 36 to 45 years age group, CHD prevalence was 8.2
and 6.4 times higher in women and men, respectively,
than in the general population. The mean age of CVD onset
(60.5 years) was higher than expected, probably because of
the selection criterion based on LDL-C.
The PAD prevalence in the present study is lower than
that described in the Spanish population.24 The prevalence
ratio of ischemic stroke between individuals with FH-P and
the general population in our study was also lower than in
other studies.24
FH-P and LLT
In our study, 13.5% of patients with FH-P were not
receiving LLT, a result comparable to other population
studies.4–6 In a recently published study, 20% of patients
with FH-P were not treated with LLT.6 Moreover, only
26.7% of patients with FH-P under LLT received intensive
or very intensive treatment. Our results also highlight the
low use of combination therapy (ie, a statin plus ezeti-
mibe).27 It is noteworthy that 48.9% of patients aged 8 to
45 years were not under LLT and only 26.7% of those
treated received high-intensity LLT. This is particularly
important because 40% of CHD occurs before 54 years
of age. This important delay in the start of treatment, often
until after the first CVD event, is exacerbated by treatment
that has LDL-C reduction capacity lower than needed.
Women with FH-P receive even less potent LLT than
men, calling attention to sex-related differences, as in other
aspects of CVD management.28 Another aspect to empha-
size is the low adherence to treatment. Only 51.2% ofFH-P participants reported high LLT adherence, similar to
other studies.29
If treatment were started before 18 years of age, the LDL
burden in patients with FH could be delayed by 5 years
compared with current initiation in older patients.30 Only
13% of children aged between 8 and 18 years with FH-P
received statin treatment in our study, compared with
65% of the patients listed in the FH pediatric register in
the United Kingdom.30 This clearly indicates an underdiag-
nosis and undertreatment in our pediatric population.
Clinical implications
In our study, age-adjusted LDL-C thresholds were useful
to screen FH. Considering that LDL-C assessment is
frequently done in clinical practice, a high proportion of
individuals with FH-P could be identified in primary
healthcare settings.31 Using electronic health records data,
we detected 3.9 times more patients with FH-P than were
recorded in the official FH Register. Our results also sup-
port opportunistic phenotypic screening in pediatric popu-
lations, together with the use of reverse screening.32
Further research is required to determine the optimal cut-
off points of LDL-C values to identify FH-P by sex. A bet-
ter understanding of the specific characteristics of FH-P
should enable the detection of those patients with FH-P at
higher risk of CVD.
Strengths and limitations of the study
SIDIAP includes epidemiologic and medical data from
85% of the Catalan population; it has enormous potential
to provide a global vision of the FH epidemiology based
on real-world data. Our study population included all
individuals who had an LDL-C test in the last 10 years,
which was 53.8% of our general population aged older
than 7 years and 68.2% in subjects aged older than
45 years; hence, we cannot discard some selection bias,
especially at younger ages. Another limitation of the study
is the lack of availability of lipoprotein (a) measurements
because high levels of it have been implied in the
diagnostic of FH.33
Zamora et al Familial hypercholesterolemia in Europe 1021Conclusions
Prevalence of FH-P in Southern Europe was higher than
initially expected. This disease is underreported and
application of the otherwise helpful genetic studies is
scarce. FH-P treatment is suboptimal, especially in women,
and could be considered at a younger age, given the high
incidence of CVD associated with FH.
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